“GLP 3” and Retatrutide: The New Triple Receptor Weight Loss Drug Everyone Is Talking About

By Dr. Henry Sobo, MD – Medical Weight Loss, Functional & Hormone Therapy, Connecticut

“GLP 3” and Retatrutide: The New Triple Receptor Weight Loss Drug Everyone Is Talking About

Health headlines and social media have started using a new term in the weight‑loss world: “GLP‑3.” Some people online even claim they are already using “GLP‑3 shots” for faster results than Ozempic. GLP‑3 is not an official drug class. It is an informal nickname for retatrutide, a powerful new triple‑agonist weight‑loss medication that is still in clinical trials and not yet FDA‑approved.

This article explains what “GLP‑3” really refers to, how retatrutide works, what the research shows so far.

What Is “GLP‑3”?

The term has emerged in media coverage and online communities as a label for retatrutide, a next‑generation injectable designed to activate three different hormone receptors involved in metabolism:

GLP‑1 (glucagon‑like peptide‑1)
GIP (glucose‑dependent insulinotropic polypeptide)
Glucagon

The logic behind the nickname is simple:

Older drugs such as semaglutide (Ozempic, Wegovy) mainly target GLP‑1 (single agonist).
Newer drugs such as tirzepatide (Mounjaro, Zepbound) target GLP‑1 and GIP (dual agonist).
Retatrutide targets GLP‑1 + GIP + glucagon, so some commentators have started calling it “GLP‑3” to suggest a third‑generation medication.

How Retatrutide Works: Triple Agonist Mechanism

Retatrutide is being developed as a once‑weekly injectable that activates GLP‑1, GIP, and glucagon receptors at the same time to influence appetite, blood sugar, and energy expenditure.

GLP‑1 receptor activation
- Reduces appetite and food intake.
- Slows stomach emptying.
- Helps improve blood sugar control.
GIP receptor activation
- Further supports insulin secretion in response to meals.
- Appears to enhance weight‑loss and glucose effects when combined with GLP‑1, based on dual‑agonist data (such as tirzepatide).
Glucagon receptor activation
- Increases energy expenditure and promotes fat oxidation when balanced properly with GLP‑1 and GIP.
- May help reduce liver fat and visceral (deep abdominal) fat, which are strongly linked to cardiometabolic risk.

By combining these three pathways, retatrutide aims to reduce appetite, improve metabolic control, and increase calorie burning more strongly than current single‑ or dual‑agonist drugs.

What Research Shows So Far

Retatrutide has been evaluated in phase 2 obesity and metabolic disease trials, with phase 3 results beginning to appear. Key findings from published and presented studies include:
- In a phase 2 obesity trial, higher‑dose retatrutide produced average weight loss of around 22.8–24.2% over 48 weeks in people with obesity.
- In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in non‑diabetic obesity cohorts.
- Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses.
These results have led several reviews to describe retatrutide as a potential “game changer” in obesity pharmacotherapy, representing the first GLP‑1/GIP/glucagon triple agonist with robust human data.
Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods.

How Retatrutide Compares to Current GLP‑1 and Dual‑Agonist Drugs

Current injectable weight‑loss drugs can be grouped roughly as:

GLP‑1 single agonists – semaglutide (Ozempic, Wegovy), liraglutide, etc.
Dual agonists (GLP‑1/GIP) – tirzepatide (Mounjaro, Zepbound).
Triple agonists – retatrutide and related investigational agents.

Systematic reviews and comparative analyses suggest the following pattern:

Dual‑agonists such as tirzepatide typically produce more weight loss than GLP‑1 single‑agonists.
Triple‑agonists such as retatrutide appear to exceed both single‑ and dual‑agonists in average body‑weight reduction in early trials.

In addition to weight loss, triple agonists are being studied for their effects on:

Liver fat and NASH/MASLD (metabolic dysfunction–associated steatotic liver disease).
Visceral abdominal fat and associated cardiometabolic risk.
Glycemic control in people with type 2 diabetes.

These broader metabolic benefits are part of the reason researchers consider triple‑agonist therapies “multi‑target” obesity and metabolic‑disease treatments rather than simple appetite suppressants.

How Medically Supervised Programs May Use Retatrutide in the Future

If ongoing trials continue to show strong benefits with acceptable safety, and if retatrutide eventually receives FDA approval, it is likely to become one more option in the toolbox for medically supervised weight‑loss programs rather than a stand‑alone miracle drug.

A careful, supervised approach would typically include:

Comprehensive evaluation before prescribing
- Detailed medical history, including prior responses to GLP‑1 or dual‑agonist medications.
- Assessment of cardiometabolic risk, liver health, and potential contraindications.
Integration with a broader metabolic plan
- Nutrition and lifestyle strategies to support insulin sensitivity, gut health, sleep, and stress.
- Use of retatrutide to enhance, not replace, underlying metabolic repair.
Close monitoring over time
- Regular follow‑up visits to track weight, body composition, labs, blood pressure, and side effects.
- Dose adjustments or therapy changes based on response and tolerability.
Maintenance planning
- Clear discussion about how to maintain results if the medication is reduced or discontinued, with emphasis on sustainable habits and metabolic health, not just the number on the scale.

Key Takeaways About “GLP‑3” and Retatrutide

“GLP‑3” is an informal nickname, not an official drug class. It refers to retatrutide, a triple‑agonist weight‑loss medication that activates GLP‑1, GIP, and glucagon receptors.
Early clinical trials show unprecedented weight‑loss results, often greater than currently approved GLP‑1 and dual‑agonist drugs, along with improvements in liver fat and metabolic markers.

As research advances and more data become available, medically supervised programs will continue to evaluate where TRIPLE‑agonist medications fit among GLP‑1 drugs, dual‑agonists, peptides, and other tools for sustainable metabolic health.

Frequently Asked Questions

What is GLP 3?

“GLP‑3” is an informal nickname used in media and online forums for retatrutide, Eli Lilly’s investigational triple‑agonist weight‑loss drug. It targets GLP‑1, GIP, and glucagon receptors simultaneously—hence the “third generation” label after single (Ozempic) and dual (Mounjaro) agonists. This term has no official medical or regulatory meaning and often appears in gray‑market peptide discussions.

Is retatrutide (GLP 3) FDA approved yet?

No, retatrutide remains in phase 3 trials as of January 2026 and is not FDA‑approved. Eli Lilly expects to complete remaining trials throughout 2026, with potential approval submission late 2026

How does GLP 3 retatrutide differ from Ozempic or Mounjaro?

Ozempic (semaglutide) is a GLP‑1 single agonist (~15–20% weight loss). Mounjaro/Zepbound (tirzepatide) is a GLP‑1/GIP dual agonist (~20–22.5% loss). Retatrutide (“GLP‑3”) is a triple agonist adding glucagon for energy expenditure and fat burning, with phase 2/3 trials showing 24–28.7% average weight loss over 48–68 weeks—potentially double semaglutide’s impact.

What weight loss results have retatrutide shown in trials?

Phase 2 trials reported 24.2% average body‑weight loss at highest doses over 48 weeks (NEJM). Recent phase 3 TRIUMPH‑4 data (Dec 2025) showed 28.7% loss over 68 weeks, exceeding semaglutide (15–17.5%) and tirzepatide (22.5%). Benefits also include liver fat reduction and better cardiometabolic markers, though long‑term data is pending.

Can retatrutide (GLP 3) be used in functional medicine programs?

Once approved, yes—under medical supervision. It could complement metabolic testing, nutrition, peptides, and lifestyle changes to enhance insulin sensitivity and fat loss.